Kraj: Francja
Język: angielski
Źródło: HMA (Heads of Medicines Agencies)
oxantel embonate 40.06 mg, praziquantel 10 mg, pyrantel embonate 9.99 mg
Vetoquinol
QP52AA51
Tablet
praziquantel, combinations
Dogs
2011-09-30
SEPTEMBER 2011 1/10 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT France EXETEC 2 United-Kingdom The Blue Cross – Dog Wormer for small dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains : Active substances Oxantel 40.06 mg (equivalent to 111.8 mg of oxantel embonate) Pyrantel 9.99 mg (equivalent to 28.8 mg of pyrantel embonate) Praziquantel 10.00 mg Excipient to one 190 mg divisible tablet Excipients For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Pale yellow to yellow, oblong tablet with breaking line. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages of nematode and cestode species: Nematodes: _ _ _Toxocara canis_ _ _ _Toxascaris leonina _ _ _ _Ancylostoma caninum_ _ _ _Uncinaria stenocephala _ _ _ _Trichuris vulpis_ Cestodes: _ _ _Dipylidium caninum_ _ _ _ _ _ _ _Taenia _spp_ _ _ _ _Echinococcus multilocularis_ _ _ _Echinococcus granulosus_ 4.3 CONTRAINDICATIONS See section 4.8. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. Fleas serve as intermediate hosts for one of the common tapeworms – _Dipylidium caninum_. Tapeworm infestation may reoccur unless control of intermediate hosts ( Przeczytaj cały dokument